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ABSTRACT
Diepoxybutane (DEB), epichlorohydrin (ECH), and 1-(chloroethenyl)oxirane (COX) are
small molecules that can form DNA interstrand cross-links. All three of these compounds
are, or are metabolites of, industrial chemicals linked to cancer. Additionally, DEB is a
metabolite of treosulfan, an anti-cancer drug. We are trying to determine why some of
these compounds cause cancer and some can also cure cancer. To do so, we are
attempting to link cytotoxicity, cross-linking efficiency, and apoptotic potential of the
three compounds to see if any correlations exist. The purpose of this project was to
quantify apoptotic potential of DEB, ECH and COX. This was done first by determining
caspase activity. These studies showed that in terms of apoptotic potential,
DEB>ECH>COX. Later studies quantified apoptosis using flow cytometry with Annexin
V/propidium iodide staining. It was determined from these studies that DEB has the
strongest apoptotic potential, and while it seems COX>ECH, more work must be done to
be sure. If it is determined that DEB>COX>ECH, this would correlate directly to crosslinking efficiency as determined in other studies. Future work may use this correlation to
mechanistically explain how some compounds cure cancer while others cause cancer.
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INTRODUCTION
Annually, the National Cancer Institute alone spends nearly 6 billion dollars on
elucidating the mechanisms of and finding treatments for cancer.1 In 2008, it was
estimated that over 1.4 million people nationwide were newly diagnosed, and nearly half
a million people died from various forms of the disease, with lung cancer as the biggest
culprit.2, 3 In 2005, cancer accounted for 22.8% of all deaths nationwide, a figure only
surpassed by heart disease. Unlike with heart disease, cerebrovascular diseases, influenza
and pneumonia, cancer is still responsible for nearly as many deaths per 100,000 people
as it was in 1950. The other diseases mentioned claim less than half as many victims as
they did over 50 years ago, and the only decreases in cancer rates have occurred in the
past ten years.3 We are finally at the brink of solving the puzzle of cancer, and continued
research is essential to a long-term decrease in the rates of people who suffer from the
dreadful disease.
Cancer can be caused by a plethora of factors, both internal and external. People
are exposed to risk factors, which when experienced alone or in combination, may lead to
cancer. Some of the most common risk factors are age, tobacco use, unprotected exposure
to UV radiation, exposure to toxic chemicals, poor diet, inactivity, and genetics.4 Cancer
can occur anywhere in the body, and the specific name of the disease is based on its
origin. The main characteristic of the disease is uncontrolled cell division. This can be
caused either be uncontrolled mitosis, or by the inability of cells to die.5
Normally, cells are meant to recycle regularly, with between 50 and 70 billion
cells committing daily suicide in a normal adult.6 These cells may be damaged, abnormal,

2

or merely in excess.5 This form of cellular death is called apoptosis, and is tightly
regulated

Figure 1: Apoptosis cascade.42 Central to this cascade are the caspase family of
proteins (pictured in pink). The cascade can be initiated by stress to the endoplasmic
reticulum, external triggers, and cellular stress. Ultimately, the process causes DNA
fragmentation, membrane blebbing, and cell shrinkage.

so that cells do not either die too rapidly or too slowly, and a happy homeostasis in
maintained.5-9 When a cell is signaled to die, either externally via a receptor that activates
a “death domain”, or internally due to damage, a cascade that activates otherwise inactive
zymogens occurs (Figure 1).5-9 The caspase family of proteins, with 13 involved
members, is at the center of this cascade. Specifically, caspase-8 is directly activated by
cleavage after an aspartate residue by the death domain and goes on to stimulate
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mitochondrial release of cytochrome c from the intermembrane space, which in turn
stimulates caspase-3 and -7, a feature that we will exploit in our studies.6-9 Ultimately,
caspases are responsible for the cell shrinkage, membrane blebbing, and nuclear
degradation that are physical characteristics of this amazing form of cellular control
(Figure 2).6, 8, 9
Cells may not always undergo apoptosis. Often, when direct damage occurs, cells
will go through necrosis, which is considered the “messy” form of cell death, as the result
is the bursting of cells (Figure 2).10 It has been found that a p53 peptide is able to
stimulate necrosis in human breast cancer cells, while leaving healthy cells alone.11
Determining whether or not compounds stimulate apoptosis or necrosis is essential in
fully understanding their effects and potential uses for treatment.

Figure 2: Morphological changes that a cell goes through once death is
initiated.43 Top shows apoptosis, which is associated with a large number of
cellular changes. Necrosis on the other hand is known as the “messy” form of
death, characterized by the lysis of the cell membrane.
When cancer occurs, there is often something wrong with the cell’s ability to
undergo apoptosis.5-7, 9 Most cancers arise from a series of mutations, which are either
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spontaneous or caused by environmental factors. DNA and specific nucleotides may
undergo deamination, hydrolysis, formation of dimers, or develop nicks in their
backbone, for example. If external chemicals are involved, bases may be deaminated or
alkylated, the latter being the focus of the Millard Lab. Alkylation of DNA by a
bifunctional agent first involves reaction of one side of the compound with a base.
Following this, the other functional group may react with water to form a monoadduct,
react with a protein to form a DNA-protein cross-link, bind to the same strand of DNA,
making an intrastrand cross-link, or bind to the opposite strand, creating an interstrand
cross-link (Figure 3).12

X

Y

Y

Monoadduct

A

Monoadduct
Intrastrand
(A = OH)
Cross-link
or
Protein-DNA cross-link
(A = protein)

Interstrand
Cross-link

Figure 3: Mechanisms through which bifunctional alkylating agents can alkylate DNA.

Normally, human cells can undergo mismatch repair, base-excision repair,
nucleotide-excision repair or direct repair to remedy any defect. However, if these
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aberrations are not resolved, or if the repair mechanism fails at replacing a damaged base
with the correct one, the mutation may become permanent and cancer may result.7 This
happens more often when two lesions occur close to each other and on opposite strands,
so that neither template is perfect.12 In addition, repair, replication and gene expression
may fail completely if alkylation results in covalently linked strands of DNA.12, 13
The link between mutagenesis and carcinogenesis is significantly greater when a
mutation occurs either in a proto-oncogene or a tumor suppressor gene. Oncogenes form
as a result of chromosomal rearrangements, chemicals, and radiation that mutate the
original sequences of genes, called proto-oncogenes, that are involved in either division
or signal transduction. These mutations are dominant, and any mutation will result in
tumor development. Mutations to tumor suppressor genes, which are responsible for
restraining cell division, may also result in tumor development. However, unlike with
oncogenes, these mutations are recessive, and both chromosomes must have a mutation in
order to develop cancer. Being born with one defective gene puts you at risk for certain
cancers, as you only need one additional mutation, but is not a death sentence. Often,
many mutations are necessary before a cell completely loses control and creates a tumor.7
Examples of two proto-oncogenes and one tumor suppressor gene that often give
rise to cancers after mutations are bcl-2, ras and p53, respectively. It was found in 1988
that the bcl-2 gene, which normally halts apoptosis by acting before cytochrome c is
released from the mitochondria, is overexpressed in many cancers due to mutations and
posttranscriptional regulatory networks.5, 6 Ras, which is mutated in over 20% of
cancers, normally helps to transduce external signals involved in growth and
differentiation.14, 15 Mutations can affect many aspects of the gene and resulting protein,
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but often alter one of three critical amino acids involved in its GTPase activity. This
results in the accumulation of a large number of active ras proteins, and growth and
differentiation is stimulated autonomously.14, 15 p53 is known as the “guardian of the
human genome.” 5 It is responsible for blocking cell division or inducing apoptosis by
releasing cytochrome c upon DNA damage. 55-70% of all cancers exhibit a damaged p53
gene.5, 7, 11
Many chemotherapy drugs that are on the market today have been found to work
by stimulating apoptosis in tumors.5, 9 The hope is that once cells are induced to undergo
apoptosis, the excess or damaged cells will proceed to die. Therapies that target apoptosis
have a wide range of mechanisms of action and include DNA cross-linking agents, DNA
fragmenting agents, antimetabolites, intercalating agents, kinase inhibitors, and
hormones. Unfortunately, it has been found that in cancers characterized by oncogene
activation and tumor suppressor gene mutation such as those mentioned above, these
drugs are unable to reverse the effects of their downstream mutations.5 Thus, it is
important to know where in the cascade the drug is stimulating apoptosis to maximize its
effectiveness.
Many chemicals that are often found to be carcinogenic also have been shown to
have anti-cancer properties, both in vivo and in vitro. The first chemical shown to exhibit
this behavior was nitrogen mustard after autopsies of soldiers exposed to the gas in World
War I showed potential therapeutic effects from the chemical.16, 17 Later, nitrogen
mustard was proved to be a bifunctional agent that exhibits its effects by cross-linking
strands of DNA, something that is particularly cytotoxic because it can physically inhibit
transcription and DNA replication.9, 12, 13, 16, 17 Many other drugs have been discovered to
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have similar properties in that they work beautifully at targeting tumor cells, but then
increase the patient’s chance of developing additional tumors later in life.18, 19 Thus, these
compounds are of particular interest to many researchers.
Since the discovery of nitrogen mustard, many additional chemicals have been
discovered to work by cross-linking DNA. This includes, but is by no means limited to,
diepoxybutane, epichlorohydrin and 1-(chloroethenyl)oxirane, which are all classified as
probable carcinogens (Figure 4). These three chemicals are the current focus of the
Millard lab, and we are trying to find out as much as we can about how they exhibit their
effects with the hope of finding a link between cross-linking efficiency, cytotoxicity and
apoptotic potential.

Cl
O
O
O

Cl
O

Diepoxybutane

Epichlorohydrin (1-Chloroethenyl)oxirane

Figure 4: Diepoxybutane, epichlorohydrin and (1-chloroethenyl)oxirane, the three
bifunctional alkylating agents currently at the center of research in the Millard Group.

Diepoxybuatane (DEB) is a potent metabolite of 1,3-butadiene, a colorless gas
that is a byproduct of ethylene production, is used in the production of plastics, rubber
and latex, and can be found in cigarette smoke and automotive emissions.20, 21 DEB is
also a metabolite of treosulfan, an anti-cancer drug.22 The Millard lab previously
determined that DEB preferentially forms interstrand cross-links at distal
deoxyguanosines at 5’-GNC sites in duplex DNA.23 Total damage in cultured cells was
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shown to be comparable in both nuclear and mitochondrial DNA.24 Exposure to
diepoxybutane has been linked to the increase in the incidence of hematopoietic and
lymphatic cancers, and inhalation exposure to DEB is highly carcinogenic, even for
weeks after exposure stops.25, 26
Epichlorohydrin (ECH) is an epoxide commonly used in the production of epoxy
resins, glycerin, elastomers, insecticides, agricultural chemicals, and other specialty
chemicals, and is classified as a probable carcinogen.21, 27 Epichlorohydrin exposure has
been found to increase the risk of lung cancer, in addition to causing chromosomal
aberrations and breaks.28, 29 Previous work in the Millard lab has shown that ECH crosslinks deoxyguanosines at both 5’-GNC and 5’-GC sites.21 Total damage in cultured cells
was found to be greater in nuclear DNA than in mitochondrial DNA.24
(1-Chloroethenyl)oxirane (COX) is a primary metabolite of !-chloroprene, a
monomer used in the production of polychloroprene (neoprene) and other synthetic
rubbers.25, 30 Chloroprene has been found to be carcinogenic via inhalation, with a major
source of the toxicity originating from its epoxide metabolites.25COX has recently been
shown to have DNA cross-linking activity, although its sequence preference has not yet
been elucidated.31
Currently, we are trying to determine the effects of DNA packaging on crosslinking by these agents. Mitochondrial DNA (mtDNA) is protected by a membrane, but
not by associated proteins. Nuclear DNA (nDNA) on the other hand, has a very intricate
system of packaging that allows nearly one meter of DNA, the approximate length of the
chicken genome, to fit within a nucleus that is less than 15 micrometers wide.7, 13, 32, 33 In
eukaryotic cells, most nDNA is not free, but is instead associated with histones. There are
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five types of histone proteins, H1, H2A, H2B, H3, and H4. Additionally, avian
erythrocytes have been found to have an additional histone, H5, that functions like H1 in
humans.34 All histones are positively charged to ease binding to negatively charged DNA.
The latter four proteins are found in duplicate and form a core octamer of one (H3,H4)2
tetramer and two (H2A, H2B) dimers. Each histone has a N-terminal tail that helps guide
nDNA around the proteins. DNA is wound left-handedly around this core approximately
1.65 times, with 147 base pairs involved in the loops (Figure 5a). The phosphate
backbone is connected to the histone proteins through multiple hydrogen bonds. These
bonds often form in the minor groove, and while they are not sequence specific, tend to
be rich in A=T pairs, due to their relative flexibility. This complex of histones and DNA
is called a nucleosome and exhibits symmetry across a dyad axis. Portions of linker
DNA, often between 20 and 70 bp, separate individual nucleosomes and make this level
of packing resemble “beads on a string” (Figure 5a). H1 binds the end of this linker DNA
to the middle of the core DNA and stimulates the next level of packing by bringing
adjacent nucleosomes closer together (Figure 5b). This initiates packing of nucleosomes
into a solenoid, which is also called the 30 nm fiber (Figure 5c). The 30 nm fiber is then
looped around a chromosomal scaffold that helps pack the nDNA into its final form.7, 13,32
nDNA that is packed into histones has an altered structure from free DNA. Not
only do the histone proteins physically block replication, recombination, repair and
transcription, but they also cause a 45o curvature in the DNA per turn around the
octamer.13, 32 Additionally, the three turns of DNA in the center are underwound, with
10.7 bp/turn, but the rest is overwound, with 10.0 bp/turn. These differences may
ultimately affect the reactivity of nDNA bound to histones as compared to free DNA.13, 35
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b
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Top View
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Figure 5: DNA condensation in humans. (a) First, DNA loops around a histone
core to form a structure resembling “beads on a string.” (b) Histone H1 then
condenses this string further and initiates formation of (c) a solenoid.32
Previous studies done in the Millard lab showed that at concentrations of 250
mM, DEB and ECH cause equivalent damage to condensed and uncondensed DNA.
Additionally, DEB damages mtDNA much more rapidly than does ECH. One of the
goals of this research is to determine whether or not these patterns are found at
concentrations closer to 10 !M, which is amount of treosulfan in patients treated with the
11

drug.36 Additionally, we are particularly interested in COX and how its reactivity in vivo
compares to the related compounds DEB and ECH.
Before we can focus on the targets of each cross-linker, we needed to conduct
apoptosis studies. As part of the apoptosis cascade, endonucleases are produced to digest
the cell’s DNA.6, 8, 9 We needed to ensure that these endonucleases were not interfering
with our DNA, so that any damage observed was due to the direct effects of the
treatment. In order to measure apoptosis, an assay testing for caspase -3 and -7 was used.
In the presence of these caspases, a substrate is cleaved and light is produced by
luciferase (Figure 6).37 Luminescence is thus directly proportional to caspase activity.
These assays were used to ensure that further experiments would not be confounded by
apoptotic endonucleases. We tested for caspase activity in cells treated with DEB, ECH
and COX, concentrations ranging from 10 !M to 1 mM and time points ranging from 2 to
24 h.
ase-3
Casp

/7

Aminoluciferin
DEVD

Luciferase

LUMINESCENCE

Figure 6: Caspase-3/7 Assay. Caspase cleaves a substrate to release aminoluciferin. The
aminoluciferin is then consumed by luciferase, causing luminescence.34

12

After determining the minimum treatment length and concentration in which
caspase is expressed, we could study the DNA targets of each chemical at lower doses
and treatment times. We used real time PCR, which fluorescently tags PCR products,
allowing quantification of PCR products as they are amplified.38 This technique allows
for easy detection of minor changes in the amount of undamaged starting DNA so that
even a small amount of damage can be detected. Our studies focused on an unexpressed,
condensed portion of the !-globin gene, an expressed portion of the folate receptor gene,
and a portion of mtDNA.
Final studies used flow cytometry to quantify cell death. Although it is not known
whether ECH and COX induce cell death via necrosis or apoptosis, recent studies in
human lymphoblasts demonstrated that DEB induces apoptosis via a mitochondrial
pathway.39 In order to measure the proportion of cells undergoing apoptosis and necrosis
in cells exposed to DEB, ECH and COX, flow cytometry was used with propidium iodide
and Annexin V staining. Propidium iodide (PI) intercalates into DNA, causing red
fluorescence. However, PI cannot enter apoptotic cells, as membrane integrity is
maintained. On the other hand, necrotic cells have lost membrane integrity, and fluoresce
red in the presence of PI (Figure 7).10 Annexin V binds to phosphatidylserines, which are
normally distributed solely on the inner cell leaflet of the plasma membrane. However, an
important part of the apoptosis cascade involves translocase activity to flip these
molecules out, so that they are exposed. Once exposed on the outer membrane, Annexin
V conjugated with FITC causes cells in apoptosis, and necrotic cells with compromised
membrane integrity, to fluoresce green (Figure 7).10, 40 When cells are stained with PI and
Annexin V-FITC, necrotic cells show high fluorescence for both, apoptotic cells only
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show high green fluorescence corresponding to Annexin V, and healthy cells show no
fluorescence (Figure 7). A chart of red versus green fluorescence for each cell is then
created. Regions can be drawn to mark levels of death, with the lower left quadrant
corresponding to healthy cells, lower right to apoptotic cells, and upper right to necrotic
cells (Figure 8). Proportions of cells in necrosis and apoptosis can then be determined by
counting cells in each region.10, 41

Figure 7: Annexin V and propidium iodide binding in varying types of death. (a)
Healthy cells exclude both Annexin V or PI, and neither binds. (b) During apoptosis,
phosphatidylserines are exposed on the outer membrane, allowing Annexin V
binding and green fluorescence. However, membrane integrity is maintained and PI
cannot enter the cell. (c) In necrosis, membrane integrity is lost and both Annexin V
and PI can bind to their respective targets, and green and red fluorescence is
detected.
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Figure 8: Flow Cytometry scattergram, with red versus green fluorescence. Cells
treated with 10 !M camptothecin for 4 h. Healthy cells do not show any fluorescence
and remain in the lower left quadrant. Apoptotic cells fluoresce green only, and are
found in the lower right quadrant. Necrotic cells show both red and green fluorescence
and are found in the upper right quadrant.

The results of this study will complement other work in the lab on the relationship
between cross-linking efficiency and cytotoxicity of DEB, ECH and COX. Previous work
has shown a correlation between cross-linking, cytotoxicity and apoptotic potential for a
family of platinum-containing compounds.41 Understanding these relationships for our
family of epoxides may provide insight into carcinogenicity versus anti-tumor potential.
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MATERIALS AND METHODS
Caution: DEB, ECH and COX are suspect carcinogens and must be handled
appropriately.
Cell Culture
Chicken 6C2 (erythro-progenitor) cells were cultured in Richter’s modified Eagle’s
medium with L-glutamine supplemented with 10% heat-inactivated fetal bovine serum,
2% heat-inactivated chicken serum, 1 M Hepes buffer, 100 units/L penicillin, 100 µg/mL
streptomycin, and 50 µM !-mercaptoethanol, all of which were run through a sterile
filter. Cells were then incubated at 37 oC with 5% CO2 and passaged to fresh media in a
1:5 (1mL cells: 4 mL fresh media), 1:10 (1 mL cells: 9 mL fresh media) or 1:20 (0.5 mL
cells: 9.5 mL fresh media) dilution every few days, or when they achieved between 80
and 90% confluence.

Treatment
Cells at 75-85% confluence were passaged into 6-well plates with a total volume of 5mL
fresh media prior to treatment with the cross-linkers. These cells were then incubated
with 1 µM to 1 mM DEB, ECH and COX for a maximum of 24 h (37 oC, 5% CO2). In
addition, 5 mL control cells were left untreated. When positive controls for apoptosis
were needed, 5mL cells were treated with camptothecin (1 to 50 µM, maximum 24 h,
positive control for apoptosis). 44
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Assessment of Apoptosis via Caspase Activity Assays
Caspase-3/7 activity was monitored in cells treated as outlined above. At various time
intervals between 2 and 24 h, 100 µL cells (less than 20,000 cells) were collected in
microcentrifuge tubes. Samples were centrifuged at 250 x g for 5 min, the pellets were
washed with 1x phosphate buffered saline solution (PBS, 137 mM NaCl, 10 mM
phosphate, 2.7 mM KCl [pH 7.4]), centrifuged again, and suspended in 100 µL PBS.
Samples were then transferred to a 96-well plate, and 100 µL of caspase-3/7 reagent
(Promega) was added for a total volume of 200 µL. Cell blanks were made up of either
100 µL cells or PBS with either 100 µL reagent or 100 µL additional PBS (total of four
blanks). Caspase activity was measured by luminescence every 15 to 30 minutes for circa
90 min (Molecular Devices Spectra Max M2).

Isolation of DNA
After cell treatment with DEB, ECH, and COX as outlined above, between 500 µL and
1.5 mL cells (less than 5 x 106 cells) were transferred to microcentrifuge tubes and spun
at 500 x g for 5 min. The supernatant was removed and cells were resuspended in 500 µL
PBS. Isolation was carried out according to the procedures included in the Qiagen
DNeasy Blood and Tissue Kit. This kit has a special spin column that is designed to bind
DNA from lysed cells. Several buffers are then used to wash the column. Pure DNA is
extracted by a final centrifugation with 200 µL elution buffer. DNA was quantified using
a NanoDrop ND-1000 UV-Vis spectrophotometer.
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Assessment of DNA Damage Using Real-Time PCR
Primers were previously designed by the Millard Lab to amplify mitochondrial DNA, a
portion of the folate receptor gene (expressed, FR), and a portion of highly condensed
chromatin at the 3’ terminus of the !-globin gene (unexpressed).24 Primer sequences were
synthesized by Integrated DNA Technologies and are as follows.
Mitochondrial : 5’- CTCCCAGCCCCATCCAACATCTCTGCTTGATGAAA and 5’TAACGGTGGCCCCTCAGAATGATATTTGGCCCCA.
FR: 5’- AAAGTACTACGCCTGGAAGAAGAGA and 5’ATTCAGAAATGGATCATGAACAAAC.
Unexpressed: 5’- AGTACTGCCGTGTGTTTGCTC and 5’TACAGCCCTCTCAGCAAGTAA.
Full Sequences of amplified regions are seen in Figure 9. PCR reactions (25 µL)
contained 12.5 µL (1x) Qiagen 2x QuantiFast SYBR Green PCR Master Mix (containing
HotStarTaq Plus DNA Polymerase, QuantiFast SYBR Green PCR Buffer, dNTP mix,
SYBR Green I, and ROX), 1µM each primer, and 15 ng template DNA. RNAase free
water was added to bring the total volume up to 25 µL. The thermal cycling was
completed in a real-time PCR cycler (Applied Biosciences StepOne Real-Time PCR
System) with the following sequence: 5 min at 95 oC, 40 cycles at 10 s 95 oC and 30 s at
60 oC. Included at the end was a melt curve built into the software. Fluorescent data were
collected during the 60 oC phase, and the amount was plotted against cycle number.
Cycle thresholds (CT) were assessed by determining the cycle at which fluorescence
exceeded 3.5 units.
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Prior to experimentation, untreated cells were cultured and PCR was performed at
each locus, as outlined above, using 50, 25, 12.5, and 6.25 ng DNA. Amount of DNA
was then plotted against average CT and it was determined that 15 ng appeared in the
linear portion of the data for each locus, so this was an appropriate amount of DNA to use
in the experiments.

Assessment of Apoptosis via Flow Cytometry
Flow cytometry was performed on cells treated as outlined above. Additionally, 500 µL
cells (~1 x 106 cells/mL) were incubated at 56 oC for 45 min to induce necrosis. After
each treatment, 5 mL cells were spun at 250 x g for 5 min and then resuspended in 2 mL
cold PBS. Cell suspensions were then counted to ensure presence of sufficient cells to
make a final concentration of 1 x 106 cells/mL in 100 !L. Cells were then prepared for
flow cytometry using an Invitrogen Vybrant Apoptosis Assay Kit #3. The 5X annexinbinding buffer included in the kit was diluted to 1X, and a 1 mg/mL stock of propidium
iodide (also included) was diluted in the 1X buffer to a final concentration of 100 µg/mL
(referred to as the working solution). Cells were then spun at 250 x g for 5 min and
resuspended in the 1X buffer to a final concentration of ~ 1 x 106 cells/mL (at least 100
µL needed for each assay). A 100 µL cell suspension was transferred to a flow cytometry
tube and 5 µL Annexin V and 1 µL working solution were added. Cells were then
incubated at room temperature for 15 min. Four hundred microliters 1X buffer was
added, and the cells were kept on ice until analysis. Cell viability was determined via
flow cytometry (BD Biosciences FACScalibur with CellQuest software). FL-3 (>575 nm,
Texas red fluorescence) versus FL-1 (530 nm, green fluorescence) plots were then
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created. The percentage of cells experiencing apoptosis was then calculated from these
scattergrams.

MITOCHONDRIAL LOCUS (376 bp)
CTCCCAGCCCCATCCAACATCTCTGCTTGATGAAATTTCGGCTCCCTATTAGC
AGTCTGCCTCATGACCCAAATCCTCACCGGCCTACTACTAGCCATGCACTACA
CAGCAGACACATCCCTAGCCTTCTCCTCCGTAGCCCACACTTGCCGGAACGTA
CAATACGGCTGACTCATCCGGAATCTCCACGCAAACGGCGCCTCATTCTTCTT
CATCTGTATCTTCCTTCACATCGGACGAGGCCTATACTACGGCTCCTACCTCT
ACAAGGAAACCTGAAACACAGGAGTAATCCTCCTCCTCACACTCATAGCCAC
CGCCTTTGTGGGCTATGTTCTCCCATGGGGCCAAATATCATTCTGAGGGGCCA
CCGTTA
UNEXPRESSED LOCUS, 3’ to !-globin gene (398 bp)
AGTACTGCCGTGTGTTTGCTCCGTAATAGTCTTGCTGGTTTACCGCACAGAAG
GTTTCATCCATTCCAGATGATTTTGTTAAGGGGAGCGACTTGAAAATGGGGA
GCTAAATGCTCTCAGCCCTCTCAATTTTCCAGCTTATTCTGCTCATGAAATCCT
TAACTTGCAATATATCCTCCAGAGAATAGGAAAACCCCACATCTAACTGTTC
AACTGCAGATAGATAAATATCAGTGCTGAATTTGTGTGCTGATTCAGTGGAA
TGCTTATATCAATTCCCAGGAATGAGCCACACGTAATCCCTATGAAAGAACC
AGTGAAGCAGTCATTTAATGGCTGTGGGTCAGCGACTTGAATGAGCTCATTTC
TTGAGCCTTTTACTTGCTGAGAGGGCTGTA
OPEN LOCUS, within FR gene (451 bp)
AAAGTACTACGCCTGGAAGAAGAGATCCTCTCCTGCCAGGATGGAGGACGTG
ACTCCTGAGGCAGGCAGAGCTGCGTGTGCTGTGCCACGGCTCACCCTGCTGC
TGGCCCTCGTGCTGCTCACTGCAGGCTGGGGGTCCTATGGGTGGGGGTCCCTG
TGACAGCTCCCTGAAGGGATGGGGCTTCTCTTTCTGCAAAGGAGGAGGCTGC
TCCCGTGGCATGAGTGGCACTTGGTCTGTTCAATTTGCTTGTGTGCCCCAGTG
GATGCTCAGCATGGACTGTGGTGTTGGACTTTGATGCCCGCTGCTGCTTCCAG
CTGGTGGAGGCAGTGATTTCCCATCCTTTGTGTCTGAGCTCCTTCTGTCTTCCC
ACCCTGTGTTTCCTGCCCATAGGACAGGTGCTGATGGCTGTGCTCTGGGTGGG
TAGTGTTTGTTCATGATCCATTTCTGAAT
Figure 9: Sequences of PCR products for each locus probed.24
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RESULTS
Caspase Assay
Levels at which DEB, ECH and COX exhibit their cytotoxic effects and induce
apoptosis in 6C2 erythro-progenitor cells were determined by monitoring caspase-3/7
activity over a range of concentrations and time points. This was done using a
proluminescent caspase-3/7 substrate that generates a luminescent signal when in the
presence of caspase -3 or -7. Concentrations ranged from 1 µM to 1 mM of each toxin.
Caspase activity was assessed at time points between 2 and 24 h. Using camptothecin at
various concentrations as a positive control, it was determined that luminescence between
950 and 9000 relative light units (RLU) is a positive indicator of apoptosis. Each trial
also included several negative controls with cells and caspase reagent, just cells, buffer
(phosphate-buffered saline solution) and caspase reagent, or just buffer. If the control
cells with caspase were found to be within the ranges mentioned above, it was
determined that the cells had overgrown in their wells and the assay was deemed
unreliable. It was determined using the negative controls that values below 400 RLU
could be attributed to noise inherent in the luminometer.
In addition to looking at raw luminescence values, data were analyzed by dividing
the luminescence of the sample by the luminescence of the control (Table 1). This
allowed complete sets of data to be analyzed by observing whether or not this value was
found to be greater than 1. Values greater than 2, along with raw luminescence of 950,
indicated apoptosis.
Cells that were treated with 250 µM and those treated with 500 µM DEB showed
apoptosis after 24 h, cells treated with 1 mM ECH showed apoptosis after 4 hours, and
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cells treated with1 mM COX showed apoptosis at 22 h (Table 2 and Figure 10).
However, the luminescence signals of the 500 µM DEB were slightly lower than 950
RLU, and time points between 12 and 24 h must be collected in order to adequately
determine apoptosis. There was no significant apoptosis observed in treatments less than
250 !M (Table 2 and Figure 11). This assay proved to be quite sensitive to time, as the
caspase signal peaks at the times given, but was not present at intervals several hours
afterwards. For the samples treated with 1 mM COX, the luminescence signal appears to
be especially sensitive to time. Qualitatively, after the 22 h time interval, the cells
appeared smaller, and membrane blebbing was seen, even though the cells no longer
showed caspase activity at 24 h. These cells resembled those of the camptothecin control
several hours after peak luminescence.
Table 1: Luminescence (RLU) of the treated cells divided by the untreated control
cells. Values shown are of dosages of DEB, ECH and COX shown to induce
apoptosis over the control. Numbers in italics are greater than 2, and with the
exception of 500 µM DEB at 24 h, which does not correspond to luminescence
above 950 RLU, denote apoptosis. An asterisk (*) denotes no data for that particular
concentration or time.

Luminesce
Samp
Luminesce
Contr
Time
(h)
4
12
24

DEB
1.14
0.90
3.52

ECH
*
*
*

500 µM

4
12
24

0.88
0.90
2.48

0.75
0.97
1.03

1 mM

4
6
12
18
22
24

4.22
1.31
*
*
*
0.83

4.26
2.93
*
1.15
0.47
2.1

Dosage
250 µM
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Table 2: Luminescence (RLU) of the treated cells divided by the untreated control
cells. Values shown are of dosages insufficient to induce apoptosis for DEB, ECH
and COX. The one value that is above 2, which corresponds to 100 µM ECH at 6 h,
is disregarded because the control cells showed high luminescence. An asterisk (*)
denotes no data for that particular concentration or time.

Dosage
25µM

Time (h)
24

Luminescence of Sample/ Luminescence of Control
DEB
ECH
COX
1.18
1.32

1.18

50µM

3
6
9
12
24

0.76
1.08
1.02
0.81
1.34

0.87
1.04
0.77
1.86
0.70

0.66
1.13
0.95
1.03
0.51

100µM

4
6
12
24

0.77
1.44
*
1.42

0.72
2.23
1.23
0.85

*
*
*
*

Figure 10: Luminescence (RLU) vs. time in luminometer (min) for samples that
yielded positive indications of apoptosis. Also included is a camptothecin at 10 µM
for 4 h as a positive control, and untreated cells with the caspase reagent as a
negative control. Clearly, apoptosis can be considered with luminescence above 950
RLU, and any values around 400 RLU resemble normal, healthy cells.
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Figure 11: Luminescence (RLU) vs. time in luminometer (min) for samples that
yielded negative indications of apoptosis. These include DEB at 25 µM and 24 h,
and all of the negative controls described, untreated cells with caspase reagent,
untreated cells with just PBS, PBS with caspase reagent and PBS alone. Also
included is a camptothecin at 10 µM for 4 h as a positive control. This shows that
luminescence below 400 RLU can be attributed to noise inherent in the machine, and
that samples with apoptosis induction luminesce in the range of 1000 RLU.
It was also established that when using longer trials, it is necessary to begin
treatment soon after transferring cells to the 6-well plates, instead of waiting 24 hours
until cells reached between 80 and 90% confluence, as was done previously. This is
because the cells are easily overcrowded and continue to multiply after treatment.
Negative controls have been shown to exhibit apoptosis after 48 hours of growth (24
hours of “preparation” and 24 hours of “treatment”). Using a 1:10 dilution of 80%
confluent cells and then treating between 4 and 6 hours later qualitatively yielded the
healthiest control cells after 24 hours.

Real Time PCR
Real time PCR was performed on chicken erythro-progenitor cells exposed to various
concentrations of DEB, ECH and COX for several time points. Before assessing for
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damage due to our cross-linking agents, standard curves were generated using varying
amounts of starting DNA template from healthy, untreated cells. All three loci,
unexpressed nDNA, expressed nDNA and mtDNA showed a region where the cycle
threshold is proportional to amount of template (Figure 12). These linear regions were
curve fitted to linear trendlines using Microsoft Excel. The unexpressed and mtDNA loci
are linear with lower amounts of template, while the expressed loci requires greater than
12.5 ng to have a linear relationship. Thus, our studies were performed with 15 ng
starting template DNA, which fell within the linear region of all three loci.

Figure 12: Standard curves generated using variable amounts of starting template
DNA. Samples were amplified using real time PCR, and the cycle at which there
is an appreciable amount of fluorescence was determined (cycle threshold, CT).
Curves were generated at three loci: (a) unexpressed nDNA, (b) expressed
nDNA, (c) mtDNA. All three curves show linear regions that have been
approximated using linear regression in Microsoft Excel.

25

We tested treatments of 10 µM for 24 h, 100 µM for 12, 18 and 24 h, and
1000 µM for 2 h, and looked at regions of expressed nDNA, unexpressed nDNA and
mtDNA. Damage was assessed by subtracting the cycle threshold of the untreated control
from the threshold of the sample. Samples with a difference greater than 0.5 were
considered significant (Table 3). It was determined that there was some evidence of
damage in the unexpressed region from 1 mM DEB and ECH after 2 h. DEB also
damaged mtDNA in the same conditions. Additionally, damage at the expressed locus by
1 mM ECH and COX was seen after 2 h. However, these results had high standard
deviations and were not always reproducible. Thus, we concluded that the regions that we
were amplifying were too short, especially at such small concentrations of our crosslinkers. Further studies are needed with new amplicons in order to determine whether or
not these results are accurate.

Table 3: Real Time PCR summary. Dosages that indicated significant damage
are highlighted in blue. Otherwise, no concentrations were significant to induce
damage at the specified locus.

DEB
ECH
COX

Unexpressed
1 mM, 2 h
1 mM, 2 h
none

Expressed
1 mM, 2h
none
1 mM, 2 h

mtDNA
1 mM, 2 h
none
none

Flow Cytometry
In order to quantify the proportion of cells undergoing apoptosis after treatment with
DEB, ECH and COX, flow cytometry with propidium iodide/Annexin V staining was
performed. Percentage of cells undergoing apoptosis or necrosis due to treatment was
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determined by subtracting the percentage of cells in the right upper and lower quadrants
from the percentage in the corresponding untreated population’s quadrants. Cells treated
with camptothecin or subjected to heat shock were assessed to serve as a benchmark for
treatment with our cross-linkers (Figure 13). It was determined that after treatment with
1 !M camptothecin for 24 h, 16% of cells were induced to be apoptotic, while 47% were
necrotic. After 10 !M camptothecin for four hours, apoptosis was induced in 40% of
cells, with no additional necrotic cells as compared to untreated cells. After 100 !M
camptothecin treatment for two hours, 17% of cells showed apoptosis induction and 6%
were necrotic.

Figure 13: Types of cell death as observed using flow cytometry with Annexin V
(FL1)/propidium iodide (FL3) staining in 6C2 cells. (a) Healthy, untreated cells. (b)
Cells induced to undergo apoptosis by camptothecin. (c) Cells induced to become
necrotic after heat shock. Percentage of cells in each quadrant is indicated.

Cells were treated with 1, 10, 100 or 1000 !M of each cross-linker for 4, 6, 12, or
24 h before assessment via flow cytometry. Preliminary results indicated that a 24 h
treatment induced apoptosis in was induced in 6.02% of cells treated with 1 mM COX
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and 10.31% of cells treated with 1 mM DEB after 24 h (Figure 15d). The sample treated
with DEB showed that an additional 5% of cells were necrotic over the untreated (data
not shown). Additionally, after 12 h, 1 !M ECH showed 6% of cells to be apoptotic and
14% to be necrotic, 10 !M DEB showed 6% of cells to be apoptotic and 5% to be
necrotic, and 10 !M COX induced apoptosis in 6% of cells and necrosis in 5% (Figure
15c).

Figure 14: Percent of apoptotic (purple) or necrotic (green) induction after
treatment with 1 !M camptothecin for 24 h, 10 !M for 4 h, or 100 !M for 2 h.

However, another set of data collected after treatment with each compound at
each dose for 24 h showed different results, with the exception of the 1000 !M DEB
sample, which still induced apoptosis in ~10% of cells (Figure 15e-f). These experiments
must be repeated in order to determine the accurate pattern of apoptosis induction.
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Figure 15: Percentage of cells with apoptosis or necrosis induced above untreated cells
after treatment with DEB, ECH or COX. Duration of treatment is indicated.
DISCUSSION
Previous and current work in the Millard research group has focused on determining
cytotoxicity, cross-linking efficiency and apoptotic potential at high concentrations of
DNA alkylating agents for short incubation times. This research has been focused on
more physiological concentrations of DEB, ECH, and COX. The studies used chicken
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erythro-progenitor cells because many alkylating agents are linked to development of
leukemia and other hematopathologies. 18, 19, 25, 26
It was first determined that DEB induces apoptosis, as determined by caspase
activity, at 250 and 500 !M, concentrations much lower than those observed in ECH and
COX. Previous studies in the Millard lab indicate apoptosis at concentrations as low as
50 !M.24 However, at 1mM, ECH shows caspase activity after four hours, while COX
requires 22. The conditions required to induce apoptosis in COX are nearly four times
those required in DEB. Thus, initial studies established that in terms of apoptotic
potential, DEB>>ECH>COX.
Many chemotheraputic agents exert their effects by inducing apoptosis in
cells.25,26 This guides cells that are not dying normally, such as tumor cells, to perish.
Thus, it may be that the increased apoptotic potential in DEB explains why its parent
compound, treosulfan, is used as an anti-cancer drug, while ECH and COX are not.
Our results are also consistent with the idea of an apoptotic window within which
caspase activity is present. It is known that the apoptosis cascade can take as little as 60
min, and if the assay is not performed within this window, the caspase has been degraded
and cells will not luminesce, even if they have died from such a cascade.8 This result was
especially evident in the 1 mM COX treated cells. COX was assayed was at 4 h, 12 h and
24 h. At 24 h, the cells appeared to be blebbing, and it looked like there was an unusual
amount of cellular debris around any remaining cells. However, these cells did not
luminesce in their assay. When repeating the trial at 18 h and 22 h, the cells showed
evidence of apoptosis at the latter. Thus, the cells must peak at 22 h, and the caspase has
been degraded by 24 h.
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Determining when the apoptotic caspase cascade is induced is particularly
important for the real time PCR studies. It is known that following caspase production
endonucleases degrade DNA.6, 8, 9 Thus, we wanted to ensure we used concentrations in
PCR well below those significant enough to induce apoptosis. Additionally, previous
studies at 250 mM doses of DEB and ECH show that ECH prefers mitochondrial DNA to
nuclear DNA, while DEB does not have a preference.24
At concentrations well below both of these criteria, it was determined that no
appreciable damage could be observed in our three amplified regions, expressed nDNA,
unexpressed nDNA and mtDNA. When moving to larger doses, it was observed that at 1
mM for two hours, DEB caused damage at all three loci, while ECH and COX only
damaged forms of nDNA. However, 1 mM was enough to induce caspase activity at
longer incubation times, so it is worrisome that these results could be produced by
endonucleases present in the apoptosis cascade. Additionally, it is possible that damage
was not observed because the amplified regions were too short to gain evidence of
significant damage at such small concentrations of cross-linking agents. Future work
should be done to design primers for a longer region that is more susceptible to damage.
Further studies must be done on DNA targets of these agents because learning
whether or not bifunctional alkylating agents have a preference for mitochondrial over
nuclear DNA will help to elucidate their mechanisms and may result in a link between
cytotoxicity, cross-linking efficiency and apoptotic potential. There are many differences
between nuclear DNA, which is often wrapped around histones, and mitochondrial DNA,
which is double stranded and circular. In addition, during cell division, the nuclear
membrane disappears, while the mitochondria DNA is always surrounded. Furthermore,
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damage to mtDNA has been implicated in apoptosis.45 All of these factors may contribute
to a molecule’s target preference, and it is necessary to know this preference before
possible mechanisms can be determined.
To conclude, studies were done to quantify apoptosis induction in cells treated
with DEB, ECH and COX. This was done using flow cytometry to test for the appearance
of phosphatidylserines using Annexin V staining, and membrane compromise by
propidium iodide. It was determined in preliminary experiments that at concentrations of
1, 10, and 100 !M, less than 6% of cells were apoptotic at any given time point. When
concentrations were raised to 1000 !M, apoptosis was seen only in cells treated with
DEB and COX. DEB induced apoptosis in almost two times as many cells as COX,
leading to the conclusion that in terms of apoptotic potential, DEB>COX>ECH.
However, this does not match with all of the flow cytometry results, and further studies
must be done to determine whether or not ECH or COX has greater apoptotic potential.
Additional experiments were done on cells treated with the full range of each
compound for 24 h. These results vary from those described above in that apoptosis is
seen after each treatment. The results still indicate that DEB is the strongest apoptosis
inducer, with the ability to induce apoptosis in nearly 25% of cells treated with 10 !M of
the compound. Additionally, like in the preliminary results, ~10% of cells are apoptotic
after treatment with 1000 !M DEB. However, it is difficult to discern whether COX or
ECH should be considered a stronger apoptotic inducer. Cells treated with COX
underwent more apoptosis at lower concentrations, but ECH was able to induce a higher
percentage of cells to die this way at higher doses. Thus, at low concentrations,
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COX>ECH, but at high concentrations, ECH>COX. In all cases, camptothecin is still
seen as having a stronger apoptotic potential.
Our results were consistent with the idea proposed by members of the Millard
group that there exists an apoptotic “window” after which cells can no longer be detected
as being apoptotic. These cells have entered into a later stage of apoptosis, characteristic
of nuclear condensation and membrane blebbing.10 We saw this in both the caspase assay
and in flow cytometry. In the caspase assay, activity was seen at 22 h after a 1 mM COX
treatment, but was not seen at 24 h. When looking at the camptothecin controls of flow
cytometry, cells treated with 1 !M for 24 h showed more cells in the necrotic region than
in the apoptotic. Additionally, in the 24 h DEB samples (Figure 15 e,f) the proportion of
cells undergoing apoptosis and necrosis had an inverse relationship. Thus, it seems that
after reaching maximum apoptosis, cells begin to die, caspase is degraded, and the
membrane becomes compromised, allowing for PI fluorescence.
Overall, it has been determined that in terms of apoptotic potential,
DEB>COX>ECH. While these results are not fully consistent with those from the
caspase assay, flow cytometry is a much more precise procedure, as it is able to count
each cell individually. These results do correlate with cross-linking efficiency of our
compounds, meaning there may be a mechanistic origin to how the compounds function
in vivo.31 Furthermore, DEB has been found to be the least cytotoxic of our three
compounds. Since it has the highest apoptotic potential, it can be seen why it is the only
one of the three currently being used as an anti-cancer drug. The amount of apoptosis
induced after treatment with 10 !M DEB during the second trial exceeds the 15%
induction found after treatment with 58 !M cisplatin for 24 h.41 It is possible that
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treosulfan, the parent compound of DEB, may have a higher anti-cancer potential as it
seems to be a stronger apoptotic inducer. The goal of any chemotheraputic agent is to kill
cancerous cells, often by inducing apoptosis, without affecting healthy cells too much.
Both of these goals are achieved with DEB, but not with ECH or COX.

CONCLUSIONS
The purpose of this study was to determine the relative apoptotic potentials of DEB, ECH
and COX. While results are not fully conclusive at this time, it appears that DEB is able
to induce apoptosis at both lower concentrations and in higher proportions than ECH and
COX. This was determined using an assay for caspase activity in addition flow
cytometry. The relationship between ECH and COX is unclear at this point, but flow
cytometry results imply that COX is able to induce apoptosis at lower concentrations than
ECH. Overall, we see that DEB, the only compound of ours that is a metabolite of an
anti-cancer drug, is the only one able to induce significant amounts of apoptosis in
chicken erythroprogenitor cells. Further work must be done to repeat all of the flow
cytometry work so that results can be confirmed. Additionally, apoptotic potential should
be determined at the LD50 values once those have been obtained. Overall, these results
are promising, and it is hoped that when coupled with cytotoxicity and cross-linking
results, a pattern will emerge that can help us predict future compounds to study.
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